Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: cortexyme.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/9/2022 | $30.00 → $15.00 | Buy | HC Wainwright & Co. |
| 1/28/2022 | $75.00 → $12.00 | Buy → Hold | Canaccord Genuity |
| 1/28/2022 | Buy → Hold | Canaccord Genuity | |
| 1/27/2022 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 10/27/2021 | Neutral → Underperform | B of A Securities | |
| 10/27/2021 | $58.00 → $15.00 | Neutral → Underperform | BofA Securities |
| 10/27/2021 | $200.00 → $30.00 | Buy | HC Wainwright & Co. |
| 9/16/2021 | $75.00 → $150.00 | Buy | Canaccord Genuity |
| 8/26/2021 | $76.00 → $200.00 | Buy | HC Wainwright & Co. |
8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)
8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
8-K - Cortexyme, Inc. (0001662774) (Filer)
8-K - Cortexyme, Inc. (0001662774) (Filer)
8-K - Cortexyme, Inc. (0001662774) (Filer)
DEFA14A - Cortexyme, Inc. (0001662774) (Filer)
S-8 - Cortexyme, Inc. (0001662774) (Filer)
8-K - Cortexyme, Inc. (0001662774) (Filer)
424B5 - Cortexyme, Inc. (0001662774) (Filer)
In overall population, co-primary endpoints of ADAS-Cog11 and ADCS-ADL were not met Pre-specified subgroups representing up to half of the participants based on P. gingivalis infection level showed approximately 50% slowing of cognitive decline Clinical data validated upstream mechanism of action and benefits of targeting P. gingivalis Additional top-line GAIN Trial results to be presented at CTAD 2021 on November 11th Cortexyme to host investor conference call today Tuesday, October 26th at 4:30 p.m. Eastern Time Cortexyme, Inc. (NASDAQ:CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company's Board of Directors. "We are very pleased to welcome a seasoned pharmaceutical and global regulatory expert of June Bray's caliber to our Board of Directors," said David Lamond, chairperson of Cortexyme's Board of Directors. "With more than four decades of pharmaceutical industry experience, we look forward to her valuable contribution and perspective across multiple therapeutic areas." "I am excited to join Cortexyme's B
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company's Board of Directors. "In conjunction with today's acquisition of Novosteo, we are very pleased to welcome a distinguished researcher, innovator, and entrepreneur of Dr. Philip Low's caliber to our Board of Directors," said David Lamond, chairman of Cortexyme's Board of Directors. "His vast expertise across targeted drug discovery, prolific research abilities, and pro
Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company Planning corporate name change to Quince Therapeutics to reflect broadening of therapeutic pipeline Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skelet
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimer's and dementia care, to the company's Board of Directors. "Dr. Sabbagh's deep expertise in neurological diseases and extensive clinical development experience makes him a valuable addition to the Cortexyme Board of Directors," said Chris Lowe, Cortexyme's interim chief executive officer. "Cortexyme will benefit greatly from his broad clinical experience as we advance our propriet
New ticker symbol (NASDAQ:QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (NASDAQ:CRTX) today announced that the company's planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics' go-forward growth strategy and development pipeline plans. Additionally, the company's ticker symbol on the Nasdaq Global Select Market is expected change to "QNCX" effective at the open of market trading on Monday, August 1, 2022. The company's common stock will continue to trade under the ticker sym
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company's lysine gingipain inhibitor in development for the treatment of Alzheimer's disease and indications with disease pathology associated with the keystone pathogen P. gingivalis. The study was a randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, an
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company's 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after oral treatment. COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition. 3CLpro, or Mpro, is a validated antiviral drug target shown to be essential in viral r
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company's Board of Directors. "We are very pleased to welcome a seasoned pharmaceutical and global regulatory expert of June Bray's caliber to our Board of Directors," said David Lamond, chairperson of Cortexyme's Board of Directors. "With more than four decades of pharmaceutical industry experience, we look forward to her valuable contribution and perspective across multiple therapeutic areas." "I am excited to join Cortexyme's B
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company's Board of Directors. "In conjunction with today's acquisition of Novosteo, we are very pleased to welcome a distinguished researcher, innovator, and entrepreneur of Dr. Philip Low's caliber to our Board of Directors," said David Lamond, chairman of Cortexyme's Board of Directors. "His vast expertise across targeted drug discovery, prolific research abilities, and pro
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Novosteo stockholders now own approximately 15.5% of the combined company. With the completion of the acquisition, Cortexyme appointed former Novosteo executives Dr. Dirk Thye as Chief Executive Officer, and Dr. Karen Smith as Chief Medical Officer of Cortexyme. Dr. Thye and Dr. Philip Low have been appointed to the Cortexyme's Boa
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at The 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases (PgLouisville2022) taking place May 15-17, 2022 in Louisville, Kentucky. Cortexyme's clinical advisory board member Mark Ryder, D.M.D., will provide an overview of GAIN Trial results and biomarker data examining the role of P. gingivalis in oral and systemic diseases. PgLouisville2022 Abstract Details Title: A Role for P. gingivalis in Alzheimer's Disease: E
Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company Planning corporate name change to Quince Therapeutics to reflect broadening of therapeutic pipeline Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skelet
Target engagement and biomarker data expands understanding of the role of P. gingivalis and the potential benefit of lysine gingipain inhibition Biomarker data and correlations to clinical outcomes consistent with the gingipain hypothesis Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, presented new target engagement and biomarker data from the GAIN Trial at the AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases. "Our understanding of the impact of lysine gingipain inhibition on neurodegeneration and other Alzheimer's diseas
Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel Sabbagh, MD, FAAN, a board-certified neurologist and leading expert in Alzheimer's and dementia care, to the company's Board of Directors. "Dr. Sabbagh's deep expertise in neurological diseases and extensive clinical development experience makes him a valuable addition to the Cortexyme Board of Directors," said Chris Lowe, Cortexyme's interim chief executive officer. "Cortexyme will benefit greatly from his broad clinical experience as we advance our propriet
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Cortexyme, Inc. (0001662774) (Issuer)
4 - Cortexyme, Inc. (0001662774) (Issuer)
3 - Cortexyme, Inc. (0001662774) (Issuer)
4 - Cortexyme, Inc. (0001662774) (Issuer)
4 - Cortexyme, Inc. (0001662774) (Issuer)
4 - Cortexyme, Inc. (0001662774) (Issuer)
4 - Cortexyme, Inc. (0001662774) (Issuer)
4 - Cortexyme, Inc. (0001662774) (Issuer)
HC Wainwright & Co. reiterated coverage of Cortexyme with a rating of Buy and set a new price target of $15.00 from $30.00 previously
Canaccord Genuity downgraded Cortexyme from Buy to Hold and set a new price target of $12.00 from $75.00 previously
Canaccord Genuity downgraded Cortexyme from Buy to Hold
JMP Securities downgraded Cortexyme from Mkt Outperform to Mkt Perform
B of A Securities downgraded Cortexyme from Neutral to Underperform
BofA Securities downgraded Cortexyme from Neutral to Underperform and set a new price target of $15.00 from $58.00 previously
HC Wainwright & Co. reiterated coverage of Cortexyme with a rating of Buy and set a new price target of $30.00 from $200.00 previously
Canaccord Genuity reiterated coverage of Cortexyme with a rating of Buy and set a new price target of $150.00 from $75.00 previously
HC Wainwright & Co. reiterated coverage of Cortexyme with a rating of Buy and set a new price target of $200.00 from $76.00 previously
Credit Suisse resumed coverage of Cortexyme with a rating of Underperform and set a new price target of $14.00